What Is Retatrutide and When Could Weight-Loss Drug Be Publicly Available?
Summary
A clinical trial shows that retatrutide, a new weight-loss drug by Eli Lilly, caused significant weight loss and improvements in conditions like knee pain and sleep apnea. Retatrutide targets three hormone receptors, unlike current drugs that only focus on one, and may help burn more fat. The drug is still being tested and has not yet been approved for public use.Key Facts
- Retatrutide is a weight-loss drug studied in a phase 3 clinical trial funded by Eli Lilly.
- It targets three hormones (GLP-1, GIP, and glucagon) to help reduce weight by making people feel full and boosting fat burning.
- The trial involved 2,339 adults with obesity, some with knee osteoarthritis and sleep apnea, lasting 18 months.
- Weight loss after treatment was dose-dependent: 17.6% loss with 4 mg, 23.7% with 9 mg, and 25% with 12 mg; placebo group lost 3.9%.
- Improvements were also seen in knee pain and sleep apnea symptoms among treated participants.
- Common side effects reported were mostly related to the digestive system.
- Retatrutide is injected, similar to some existing drugs like Wegovy and Ozempic.
- The drug has not yet been approved by the U.S. Food and Drug Administration (FDA).
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
